INO-3107 Expected Cash Sufficient into Q1 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Estimates current cash, cash equivalents and short-term investments balances sufficient into 1Q27, beyond the target PDUFA date for INO-3107. Reports Q1 revenue $0, consensus $250K. "We remain focused on advancing INO-3107 toward its target PDUFA date to ensure that every RRP patient has access to therapeutic options that work for them to reduce the need for surgery. We believe there remains a critical unmet need among patients diagnosed with this rare and devastating disease, and that INO-3107 has the potential to become the preferred product by patients and their physicians, if approved, based on clinical results, tolerability data and the simplicity of its patient-centric treatment regimen that does not require additional surgeries during the dosing window," said CEO Jacqueline Shea. "While the BLA for INO-3107 is under active review, we continue to advance our commercial readiness plans in anticipation of a 2026 approval, as well as leverage the power of partnerships to advance other promising candidates in our pipeline."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.070
Low
3.00
Averages
7.33
High
13.00
Current: 1.070
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Inovio Pharmaceuticals Executives for Breach of Fiduciary Duties
- Investigation Launched: Kuehn Law, PLLC is investigating whether executives at Inovio Pharmaceuticals breached their fiduciary duties to shareholders, with a federal securities lawsuit indicating potential misrepresentation by insiders regarding the company's status.
- Manufacturing Deficiencies: The investigation highlights deficiencies in the manufacturing of Inovio's CELLECTRA device, which may delay the submission of the INO-3107 BLA to the FDA until the second half of 2024, impacting future product timelines.
- Uncertain Regulatory Outlook: Due to insufficient information to justify INO-3107's eligibility for accelerated approval or priority review, the overall regulatory and commercial prospects of the product are considered overstated, potentially harming shareholder returns.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorneys promptly to protect their rights, emphasizing the importance of participation and how shareholder voices are crucial for maintaining the integrity of financial markets.
See More
Inovio Pharmaceuticals Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether Inovio Pharmaceuticals executives breached their fiduciary duties to shareholders, with the ongoing litigation potentially impacting the company's reputation and shareholder confidence.
- Manufacturing Defects Exposed: The lawsuit alleges deficiencies in the manufacturing of Inovio's CELLECTRA device, resulting in the company's inability to timely submit the INO-3107 Biologics License Application (BLA) to the FDA, which could affect future product launch timelines.
- Regulatory Outlook Uncertain: Due to insufficient information to justify INO-3107's eligibility for accelerated approval or priority review, the company's regulatory and commercial prospects are deemed overstated, which may lead to a decline in investor confidence.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased INO stock before October 10, 2023, to contact them promptly to protect their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining integrity in financial markets.
See More
INOVIO to Participate in Global Healthcare Conferences
- Conference Participation: INOVIO will participate in the Jefferies Global Healthcare Conference on June 4 at 8:45 AM ET, aiming to enhance its visibility among investors and showcase the potential of its DNA medicines.
- Rare Disease Presentation: At the World Orphan Drug Congress on June 11, INOVIO will present a poster titled 'Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine,' highlighting its innovations in treating rare diseases.
- Investor Meeting Arrangements: INOVIO's management team will conduct one-on-one meetings with investors during the investor conference, aiming to strengthen relationships with potential investors and drive funding support for its DNA medicine development.
- Technological Advantage Introduction: INOVIO focuses on developing and commercializing DNA medicines, utilizing its technology to optimize the design and delivery of innovative drugs that help the body manufacture its own disease-fighting tools, thus showcasing significant market potential in treating HPV-related diseases and cancer.
See More
Inovio's Partner ApolloBio Achieves Phase 3 Trial Success
- Clinical Trial Success: ApolloBio's Phase 3 trial for the VGX-3100 vaccine successfully met its predefined primary efficacy endpoint, demonstrating a favorable safety and tolerability profile without new safety concerns, which is expected to support regulatory approval in China.
- Significant Market Potential: VGX-3100 targets human papillomavirus, the most common sexually transmitted infection, and successful commercialization could address the urgent need for cervical dysplasia treatment in China, potentially generating substantial economic returns.
- Milestone Payment Opportunities: Inovio is entitled to receive up to $20 million in milestone payments upon ApolloBio's approval of VGX-3100, along with tiered royalties on net sales, which will significantly enhance the company's financial position.
- Broad Collaboration Prospects: The success of this clinical trial not only boosts Inovio's brand influence in the Chinese market but also lays the groundwork for further collaboration with ApolloBio, potentially driving the development and commercialization of more innovative therapies.
See More
INOVIO's Cervical Dysplasia Therapy Trial Achieves Success
- Trial Success: ApolloBio's final-stage clinical trial for INOVIO's cervical dysplasia treatment met its primary goal, demonstrating the therapy's ability to reverse precancerous changes and clear high-risk HPV, indicating significant therapeutic potential.
- Good Safety Profile: The trial confirmed a favorable safety profile with no major new side effects reported, providing strong support for future approval applications in China, which could expedite market entry.
- Financial Incentives: Under the partnership agreement, INOVIO could receive up to $20 million in milestone payments and royalties if the treatment is approved and sold in the licensed region, significantly enhancing the company's financial outlook and competitive position.
- Positive Market Reaction: Following the announcement of the trial results, INOVIO shares rose 3% in after-hours trading, reflecting investor optimism about the therapy's prospects, despite a 33% decline in stock price over the past year.
See More
Inovio Pharmaceuticals Q1 2026 Earnings Call Insights
- Regulatory Progress: CEO Jacqueline Shea indicated that the FDA's mid-cycle review raised no new issues, with a late-cycle review scheduled for Q3, establishing a solid foundation for the October 30, 2026 PDUFA date and reducing approval risks.
- Financial Update: As of Q1 2026, Inovio reported $37.7 million in cash and short-term investments, down from $58.5 million as of December 31, 2025; however, the April public offering is expected to extend the cash runway into Q1 2027, ensuring operational continuity.
- Commercialization Readiness: Chief Commercial Officer Steven Egge revealed plans for self-managing commercialization with support from a contract sales organization, reflecting confidence in market entry and a strategy for differentiating from existing products.
- Operating Expense Reduction: Operating expenses decreased from $25.1 million in Q1 2025 to $21.9 million in Q1 2026, a 13% reduction, indicating significant progress in cost control, which will help improve overall financial health.
See More
Investigation into Inovio Pharmaceuticals Executives for Breach of Fiduciary Duties
- Investigation Launched: Kuehn Law, PLLC is investigating whether executives at Inovio Pharmaceuticals breached their fiduciary duties to shareholders, with a federal securities lawsuit indicating potential misrepresentation by insiders regarding the company's status.
- Manufacturing Deficiencies: The investigation highlights deficiencies in the manufacturing of Inovio's CELLECTRA device, which may delay the submission of the INO-3107 BLA to the FDA until the second half of 2024, impacting future product timelines.
- Uncertain Regulatory Outlook: Due to insufficient information to justify INO-3107's eligibility for accelerated approval or priority review, the overall regulatory and commercial prospects of the product are considered overstated, potentially harming shareholder returns.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact their attorneys promptly to protect their rights, emphasizing the importance of participation and how shareholder voices are crucial for maintaining the integrity of financial markets.
See More
Inovio Pharmaceuticals Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether Inovio Pharmaceuticals executives breached their fiduciary duties to shareholders, with the ongoing litigation potentially impacting the company's reputation and shareholder confidence.
- Manufacturing Defects Exposed: The lawsuit alleges deficiencies in the manufacturing of Inovio's CELLECTRA device, resulting in the company's inability to timely submit the INO-3107 Biologics License Application (BLA) to the FDA, which could affect future product launch timelines.
- Regulatory Outlook Uncertain: Due to insufficient information to justify INO-3107's eligibility for accelerated approval or priority review, the company's regulatory and commercial prospects are deemed overstated, which may lead to a decline in investor confidence.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased INO stock before October 10, 2023, to contact them promptly to protect their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining integrity in financial markets.
See More
INOVIO to Participate in Global Healthcare Conferences
- Conference Participation: INOVIO will participate in the Jefferies Global Healthcare Conference on June 4 at 8:45 AM ET, aiming to enhance its visibility among investors and showcase the potential of its DNA medicines.
- Rare Disease Presentation: At the World Orphan Drug Congress on June 11, INOVIO will present a poster titled 'Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine,' highlighting its innovations in treating rare diseases.
- Investor Meeting Arrangements: INOVIO's management team will conduct one-on-one meetings with investors during the investor conference, aiming to strengthen relationships with potential investors and drive funding support for its DNA medicine development.
- Technological Advantage Introduction: INOVIO focuses on developing and commercializing DNA medicines, utilizing its technology to optimize the design and delivery of innovative drugs that help the body manufacture its own disease-fighting tools, thus showcasing significant market potential in treating HPV-related diseases and cancer.
See More
Inovio's Partner ApolloBio Achieves Phase 3 Trial Success
- Clinical Trial Success: ApolloBio's Phase 3 trial for the VGX-3100 vaccine successfully met its predefined primary efficacy endpoint, demonstrating a favorable safety and tolerability profile without new safety concerns, which is expected to support regulatory approval in China.
- Significant Market Potential: VGX-3100 targets human papillomavirus, the most common sexually transmitted infection, and successful commercialization could address the urgent need for cervical dysplasia treatment in China, potentially generating substantial economic returns.
- Milestone Payment Opportunities: Inovio is entitled to receive up to $20 million in milestone payments upon ApolloBio's approval of VGX-3100, along with tiered royalties on net sales, which will significantly enhance the company's financial position.
- Broad Collaboration Prospects: The success of this clinical trial not only boosts Inovio's brand influence in the Chinese market but also lays the groundwork for further collaboration with ApolloBio, potentially driving the development and commercialization of more innovative therapies.
See More
INOVIO's Cervical Dysplasia Therapy Trial Achieves Success
- Trial Success: ApolloBio's final-stage clinical trial for INOVIO's cervical dysplasia treatment met its primary goal, demonstrating the therapy's ability to reverse precancerous changes and clear high-risk HPV, indicating significant therapeutic potential.
- Good Safety Profile: The trial confirmed a favorable safety profile with no major new side effects reported, providing strong support for future approval applications in China, which could expedite market entry.
- Financial Incentives: Under the partnership agreement, INOVIO could receive up to $20 million in milestone payments and royalties if the treatment is approved and sold in the licensed region, significantly enhancing the company's financial outlook and competitive position.
- Positive Market Reaction: Following the announcement of the trial results, INOVIO shares rose 3% in after-hours trading, reflecting investor optimism about the therapy's prospects, despite a 33% decline in stock price over the past year.
See More
Inovio Pharmaceuticals Q1 2026 Earnings Call Insights
- Regulatory Progress: CEO Jacqueline Shea indicated that the FDA's mid-cycle review raised no new issues, with a late-cycle review scheduled for Q3, establishing a solid foundation for the October 30, 2026 PDUFA date and reducing approval risks.
- Financial Update: As of Q1 2026, Inovio reported $37.7 million in cash and short-term investments, down from $58.5 million as of December 31, 2025; however, the April public offering is expected to extend the cash runway into Q1 2027, ensuring operational continuity.
- Commercialization Readiness: Chief Commercial Officer Steven Egge revealed plans for self-managing commercialization with support from a contract sales organization, reflecting confidence in market entry and a strategy for differentiating from existing products.
- Operating Expense Reduction: Operating expenses decreased from $25.1 million in Q1 2025 to $21.9 million in Q1 2026, a 13% reduction, indicating significant progress in cost control, which will help improve overall financial health.
See More
